4.7 Review

Focusing COVID-19-associated mucormycosis: a major threat to immunocompromised COVID-19

Journal

ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
Volume 30, Issue 4, Pages 9164-9183

Publisher

SPRINGER HEIDELBERG
DOI: 10.1007/s11356-022-24032-2

Keywords

Antifungal therapy; Black fungus; COVID-19-associated mucormycosis; Pulmonary mucormycosis; Rhino-orbital-cerebral mucormycosis

Ask authors/readers for more resources

COVID-19 disease has led to a significant increase in cases of mucormycosis infection in India, primarily among individuals recovering from COVID-19. This poses a serious threat to immunocompromised COVID-19 patients and is associated with severe clinical complications and elevated death rate.
COVID-19 disease has been identified to cause remarkable increase of mucormycosis infection cases in India, with the majority of cases being observed in individuals recovering from COVID-19. Mucormycosis has emanated as an outcome of the recent COVID-19 pandemic outbreak as rapidly developing fatal illness which was acquired by Mucorales fungus which is a subcategory of molds known as mucormycetes. Mucormycosis is one of the serious, sporadic mycotic illnesses which is a great threat to immunocompromised COVID-19 patients and affects people of all ages, including children with COVID-19 infections. This is associated with tissue damaging property and, therefore, causes serious clinical complications and elevated death rate. The COVID-19-associated mucormycosis or black fungus are the terms used interchangeably. The rapid growth of tissue necrosis presenting as rhino-orbital-cerebral, pulmonary, cutaneous, gastrointestinal, and disseminated disease are various clinical forms of mucormycosis. The patient's prognosis and survival can be improved with proper surgeries using an endoscopic approach for local tissue protection in conjunction with course of appropriate conventional antifungal drug like Amphotericin-B and novel drugs like Rezafungin, encochleated Amphotericin B, Orolofim, and SCY-078 which have been explored in last few years. This review provides an overview of mucormycosis including its epidemiology, pathophysiology, risk factors, its clinical forms, and therapeutic approaches for disease management like antifungal therapy, surgical debridement, and iron chelators. The published patents and ongoing clinical trials related to mucormycosis have also been mentioned in this review.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available